Clinical Outcomes and Molecular Biomarkers of Response to Pembrolizumab plus Fulvestrant in ER+/HER2− Metastatic Breast Cancer: Results from a Big Ten Cancer Research Consortium Multicenter Phase II Study
In a multicenter Phase II study of ER+/HER2− metastatic breast cancer, the combination of pembrolizumab and fulvestrant demonstrated a manageable safety profile and a 36.4% clinical benefit rate with durable responses in a subset of patients, although these outcomes did not correlate with PD-L1 status.